Skip Navigation LinksHome > April 14, 2000 - Volume 14 - Issue 6 > Impaired induction of IL-15 in response to herpes simplex vi...
AIDS:
Correspondence

Impaired induction of IL-15 in response to herpes simplex virus type 1 infection in peripheral blood mononuclear cells of HIV-infected patients

Ahmad, Aliacd; Ahmad, Rasheedac; Toma, Emilbc; Morisset, Richardbc; Menezes, Joséac

Free Access
Article Outline
Collapse Box

Author Information

aSte-Justine Hospital, bHôtel-Dieu Hospital and cDepartment of Microbiology and Immunology, University of Montreal, 3175 Côte Ste-Catherine, Montreal, Quebec, Canada H3T 1C5. dCorresponding author

Sponsorship: This work was supported by a research grant from the Medical Research Council of Canada.

Received: 23 December 1999; accepted: 7 January 2000.

IL-15 is a relatively novel cytokine that shares many biological activities with IL-2 [1,2]. The two cytokines have similar tertiary structure, and use β and γ chains of the IL-2 receptor complex for binding and signal transduction. However, unlike IL-2, which is produced by activated T cells, IL-15 is produced from a wide variety of cells and tissues in the body. Furthermore, it has a unique receptor component (α-chain), which also has much wider cell and tissue distribution compared with its corresponding α-chain for IL-2. In blood, monocyte-macrophages represent the main cell type that produces IL-15. This cytokine markedly increases the cytolytic potential of natural killer (NK) and cytotoxic T cells, and induces proliferation and antibody secretion in antigen-activated B cells. In vivo, it has been shown to be essential for the development and maturation of NK cells [1,2]. IL-15 is induced in the host as a defence to viral and non-viral intracellular pathogens. Human herpesviruses have been demonstrated to enhance NK activity of human peripheral blood mononuclear cells (PBMC) via IL-15 induction [3,4]. The enhanced NK activity is well known to play a role in the control of these infections [5].

AIDS, which results from infection with HIV-1, is accompanied by decreased resistance of the infected individuals to opportunistic infections including herpesviruses. Decreased NK activities and defective antimicrobicidal potential of the macrophages have been well documented in HIV-infected individuals [6,7]. The decreased NK activities occur even in the early stages of the infection [6]. The reasons for this decrease are not fully understood. Reduced production of the NK activity-enhancing cytokines, e.g. IL-2 and IL-12 has been reported in HIV-infected individuals [8,9]. However, few studies have been conducted to investigate the role of IL-15 in these infections.

In order to investigate the capacity of HIV-infected individuals to induce IL-15 in response to a herpesviral infection, we obtained PBMC from 12 of these individuals as well as from age-matched HIV-seronegative control subjects after their informed consent. The HIV-infected individuals represented all stages of the infection, were not on highly active antiretroviral therapy and had one or more AIDS-defining conditions. Four million PBMC from each donor were infected in vitro with 50 μl of a herpes simplex virus type 1 (HSV-1) viral preparation that was produced in VERO cells and contained 1 × 108 plaque-forming units per millilitre. After infection at 37°C for 1 h, the cells were washed and incubated in one millilitre of the culture medium (RPMI-1640 with 10% heat-inactivated fetal bovine serum and antibodies). Twenty four hours later, the culture supernatants were collected and passed through 0.2 μ filters. These supernatants were concentrated 10-fold for proteins by using filters (Microconcentrator 10; Amicon, Beverly, MA, USA), and their IL-15 content was determined using a commercial enzyme-linked immunosorbent assay kit (Immunocorp, Montreal, Canada). The results obtained from these determinations are shown in Fig. 1. On average, the PBMC from HIV-infected/AIDS patients secreted less IL-15 than their HIV-seronegative counterparts in response to HSV-1 infection. IL-15 was not detectable in similarly prepared supernatants from mock-infected PBMC (except for three HIV-infected donors); the average optical density values of enzyme-linked immunosorbent assay between the two groups of donors did not differ significantly (P  > 0.05; data not shown).

Fig. 1
Fig. 1
Image Tools

These results suggest that there is compromised induction of the IL-15 gene in the PBMC of HIV-infected individuals in response to HSV-1 infection. This virus is known to enhance the NK activity of human PBMC in vitro; however, this enhancement is much less in HIV-infected individuals compared with the HIV-seronegative controls [10]. Our results suggest that impaired IL-15 production in the PBMC of the infected individuals may be one of the reasons for their less than normal increase in NK activity in response to HSV-1 infection. Our results are corroborated by those of Chehimi et al. [11], who also reported decreased production of IL-15 in response to a bacterial infection in the PBMC of HIV-infected individuals compared with HIV-seronegative control subjects. In addition to IL-2 and IL-12, HIV-infected individuals thus also seem to produce less IL-15 upon stimulation. Although IL-15 enhances immune function and the expansion of virus-specific cytotoxic T lymphocytes in HIV infections [11,12], it has also been incriminated in the polyclonal B cell activation and T cell-induced alveolitis in AIDS patients [13,14]. Clearly, further studies are needed to investigate how this important cytokine is modulated in the course of HIV infections.

Ali Ahmadacd

Rasheed Ahmadac

Emil Tomabc

Richard Morissetbc

José Menezesac

Back to Top | Article Outline

References

1. Tagaya Y, Bamford RN, deFilipis AP, Waldmann TA. IL-15: a pleiotropic cytokine with diverse receptor/signaling pathways whose expression is controlled at multiple levels. Immunity 1996, 4: 329–336.

2. Waldmann TA, Tagaya Y. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in the NK cell differentiation and host response to intracellular pathogens. Annu Rev Immunol 1999, 17: 19–49.

3. Flamand L, Stefanescu I, Menezes J. Human herpes virus-6 enhances natural killer cytotoxicity via IL-15. J Clin Invest 1996, 97: 1373–1381.

4. Atedzoé BN, Ahmad A, Menezes J. Enhancement of natural killer cell cytotoxicity by the human herpesvirus-7 via IL-15 induction. J Immunol 1997, 159: 4966–4972.

5. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 1999, 17: 189–220.

6. Ullum H, Gotzsche PC, Victor J, Dickmeiss E, Skinhoj P, Pederson BK. Defective natural immunity: an early manifestation of human immunodeficiency virus infection. J Exp Med 1995, 182: 789–799.

7. Ahmad A, Menezes J. Antibody-dependent cellular cytotoxicity in HIV-infections. FASEB J 1996, 10: 258–266.

8. Chemimi J, Starr SE, Frank I. et al. Impaired interleukin 12 production in human immunodeficiency virus-infected patients. J Exp Med 1994, 179: 1361–1366.

9. Fan J, Bass HZ, Fahey JL. Elevated INF-γ and decreased IL-2 gene expression are associated with HIV-infection. J Immunol 1993, 151: 5031–5040.

10. Hersh EM, Gutterman JU, Spector S. et al. Impaired in vitro interferon, blastogenic and natural killer cell responses to viral stimulation in acquired immune deficiency syndrome. Cancer Res 1985, 45: 406–410.

11. Chehimi J, Marshall JD, Salvucci O. et al. IL-15 enhances immune functions during HIV infection. J Immunol 1997, 158: 5978–5987.

12. Kanai T, Thomas EK, Tasutomi Y, Letvin NL. IL-15 stimulates the expansion of AIDS virus-specific CTL. J Immunol 1996, 157: 3681–3687.

13. Kacani L, Stoiber H, Dierich MP. Role of IL-15 in HIV-1-associated hypergammaglobulinemia. Clin Exp Immunol 1997, 108: 14-18.

14. Agnosti C, Trentin L, Sancetta R. et al. Interleukin-15 triggers activation and growth of the CD8 T-cell pool in extravascular tissues of patients with acquired immunodeficiency syndrome. Blood 1997, 90: 1115–1123.

© 2000 Lippincott Williams & Wilkins, Inc.

Login